Strategic focus TheraVectys specializes in lentiviral vector technology for immunotherapy, with a joint-laboratory model between a private company and the Institut Pasteur. This positions them as a high-expertise partner for collaborations in cancer and infectious disease vaccines and therapies.

Funding leverage Recent financing of 20M USD signals investor confidence and potential for accelerated R&D and partnerships. Use this to approach co-development discussions, grant-ready projects, or milestone-based deals.

Geographic reach Operations in Paris and the USA indicate cross-border collaboration potential and access to Western biotech ecosystems. Opportunities for international partnerships, technology licensing, and joint ventures across markets.

Early-stage revenue profile Current revenue is modest (0–1M USD) with substantial funding, suggesting the company may be open to collaboration models, contract research, or joint development agreements rather than sole product sales in the near term.

Pipeline and IP strength A robust pipeline of vaccine candidates and proprietary lentiviral vector platform, backed by Pasteur's virology expertise, offers multiple touchpoints for strategic partnerships, licensing, and co-development with pharma/biotech players seeking novel immunotherapy modalities.